This FTSE 250 dividend stock and investment trust bargain may help you play the emerging markets crisis

This FTSE 250 (INDEXFTSE: MCX) emerging markets specialist is defying the current meltdown but the sector remains risky, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Emerging markets are on the rack right now. China is number one target in President Trump’s trade war. Venezuela is in meltdown. Argentina and Turkey are embattled, and there are growing concerns about India and South Africa. Contagion could even spread to the West. However, threats like these also bring opportunities for brave investors.

Emerging fears

The strong dollar is at the heart of it. Emerging market countries have loaded up on cheap dollar-denominated debt over the last decade but now it is proving difficult to service, as interest rates rise and QE is reined-in.

As a specialist emerging markets asset manager, FTSE 250 listed Ashmore Group (LSE: ASHM) should be in the firing line, but today’s trading update for the first quarter to 30 September is positive. It posted net inflows of $1.9bn as clients looked to take advantage of recent price volatility, a trend management expects to continue. 

Flowing in

Ashmore grew assets under management by a respectable 3.4% as $2.5bn of inflows lifted its total to $ It was further boosted by positive market movements of $300m and a similar amount of acquired assets.

CEO Mark Coombs said current uncertainty is leading to mis-pricing, which is throwing up buying opportunities. “We anticipate there will be more opportunities to buy attractively-valued assets and to embed long-term value into portfolios.” We like that kind of fighting talk at the Fool.


One concern is that the valuation doesn’t reflect current uncertainties, as it trades at 16.4 times forecast earnings. Also, share price performance does not reflect its buoyancy, with the stock trading 14% lower than five years ago. It does yield 4.8%, though, with cover of 1.3. My Foolish colleague Kevin Godbold admires its dividend potential. I just wish Ashmore was a mis-pricing opportunity too.

Fund manager Mark Mobius is the doyenne of emerging markets investing, and many still link his name with his trail-blazing investment trust Templeton Emerging Markets (LSE: TEM), which he helmed for 26 years before his recent replacement by Chetan Sehgal, who may be having a baptism of fire.

Interesting times

The fund is up just 22% measured over five years but still beat the wider investment trust global emerging markets sector, up 14% in that time. Over three years it is up 52%, against 29% for its sector. The new manager has had a rough ride, though, with the trust trading 14.5% lower than 12 months ago, worse performance than the sectoral dip of 11.2%.

The £1.67bn giant, launched in 1989, contains big and familiar tech names, including Chinese behemoths Alibaba Group and Tencent Holdings, Samsung Electronics and Taiwan Semiconductor Manufacturing, Indian bank ICICI and Unilever. Tencent has just suffered the biggest market value loss in history, a world record $220bn, hitting the trust’s performance.

Lonely are the brave

A quarter of the fund is invested across Asia-Pacific, with meaty exposure to South Korea and Taiwan, then a broad spread across Russia, Brazil, South Africa, India and Thailand. This gives you a good global reach. It is also trading at a discount of 11.9% to net asset value. Didn’t I say that you need to be brave, though?

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

harveyj has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A pastel colored growing graph with rising rocket.
Investing Articles

How much passive income could I make for every £1,000 invested in Aviva shares?

Even a relatively small investment in Aviva shares could generate much greater passive income, particularly if the dividends are reinvested…

Read more »

Close-up of British bank notes
Investing Articles

I’m considering 100 shares in this FTSE 250 gem to aim for £300 a month in dividends

Mark Hartley outlines why a lesser-known banking stock from the FTSE 250's worth considering for an income portfolio in 2024.

Read more »

Investing Articles

History suggests these UK shares might soar if interest rates are cut in August

Some UK shares could rocket if interest rates fall from its 5.25% high next month. And there's one our writer…

Read more »

Female Doctor In White Coat Having Meeting With Woman Patient In Office
Investing Articles

Here’s why H1 results could boost the AstraZeneca share price

The AstraZeneca share price has been a success story in the past five years. With H1 results due, can it…

Read more »

Investing Articles

£17,365 in savings? Here’s how I’d use it to target a £6,700-a-month passive income

Here's how a lump sum investment could pave the way for me to make a four-figure monthly passive income in…

Read more »

Investing Articles

Down more than 10% in 6 months, Fools are backing these 5 UK stocks to reverse that – and then some! – by 2025

Some of our UK free-site writers have put forward their candidates for turnaround stocks!

Read more »

Investing Articles

Down 23%! Should I buy more CrowdStrike shares for my Stocks and Shares ISA?

Sometimes bad news can be good news for long-term investors. But is that the case for CrowdStrike in relation to…

Read more »

Investing Articles

2 UK shares near 52-week lows I’m considering snapping up

These UK shares are loitering near, or at, 52-week lows. Are these prime opportunities for our writer to boost her…

Read more »